Different activating mutations have been identified in the melanoma subtypes of molecules that are part of this pathway, such as N-RAS, BRAF, MEK, and ERK; in fact, more than half of the reported melanoma mutations correspond to BRAF V600E [62,63]. This evidence concerns the gene MAP2K7 and melanoma.